contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

It went to the public sector, so at some point it must have been in Hilma.

hankintailmoitukset.fi              Hilma                              I wonder if it’s this one or if this is something else? I don’t think this has popped up here yet?

University Hospital in Finland Orders a Nexstim NBS 6 System Press release, Helsinki, 10 March 2026 at 9 AM (EET) Nexstim Plc (“Nexstim” or “Company”) has received an order for an NBS 6 diagnostics system from a university hospital in Finland. The customer is an experienced Nexstim system user. After the system delivery, the customer will be able to use both of their NBS 6 Systems integrated with the data management system. In October 2025, the Nexstim received MDR (Regulation (EU) 2017/745) certification for the NBS 6 for the pre-procedural mapping of the speech and motor cortices of the brain. The NBS 6 system is also CE-marked for the treatment of major depression and chronic neuropathic pain, as well as for the post-operative rehabilitation of motor deficits of the upper limb. NBS 6 is a new combination system built on Nexstim’s unique, clinically established E-field navigated TMS (transcranial magnetic stimulation) technology, with a modular system concept that allows system capabilities to expand over time and be highly customized based on a customer’s research or clinical interests. Mikko Karvinen, CEO of Nexstim, comments: “We are happy to see our customers in our home market get access to our new system generation that is now available for both diagnostics and therapy use. This customer gains great benefit from the flexibility and usability that our combination system brings.”

Cognito has a Phase 3 trial ongoing, and results are expected in August. I don’t know how comparable Cognito’s and Sinaptica’s Phase 2 trials are, but both were around the 75-80% range compared to the control group. Sinaptica’s results are percentage-wise better (according to AI). Could these two products have a symbiosis instead of competing with each other? The Sinaptica and Nexstim setup must be administered at a clinic, whereas, as I understand it, Cognito’s device is indeed designed for home use. Given this, it would be surprising if Sinaptica cannot secure its funding.

Medical tech should otherwise be immune, but rising interest rates obviously have an impact. I’m still a bit surprised that they are among the top decliners.

Surprisingly, the general market gloom is hitting Nexstim. When the war in Ukraine broke out, Nexstim was quite immune to the general market downturn. However, the rise in oil prices is unlikely to drastically affect the price of Nexstim’s products or even the buyers’ finances.

Nexstim has a small stake in Sinaptica… it could prove to be valuable at some point.  Nexstim is available at 8.50 today. Is it starting to be time to add?

Nexstim

Nexstim is a medical technology company whose transcranial magnetic stimulation systems are used in pre-operative brain mapping and to treat neurological diseases and disorders. The company is a technologically advanced niche player in large markets supported by megatrends. Nexstim is still in an early stage of commercialization and seeking sustainable positive earnings.

<p>Nexstim is a medical technology company whose transcranial magnetic stimulation systems are used in pre-operative brain mapping and to treat neurological diseases and disorders. The company is a technologically advanced niche player in large markets supported by megatrends. Nexstim is still in an early stage of commercialization and seeking sustainable positive earnings. The valuation of the share relies heavily on future expectations of system sales growth, licensing income recognition and expansion of the new clinic network model. We find the valuation reasonable but it does not provide investors sufficient expected return relative to the risks at the current level. </p> 

	2022	23e	24e
Revenue	9.5	6.3	8.5
growth-%	48.9 %	-34.2 %	35.2 %
EBIT (adj.)	0.8	-1.8	-0.4
EBIT-% (adj.)	8.8 %	-28.9 %	-5.2 %
EPS (adj.)	0.18	-0.26	-0.07
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	22.8	neg.	neg.
EV/EBITDA	22.0	neg.	378.1

Nexstim: Growth initiatives waiting for lift-off

Key Estimate Figures28.09.2023

Forum discussions